EHC
Encompass Health Corporation
EHC's fundamentals are strong: revenue grew 9.4% and earnings per share grew 21%. At 22x earnings, it's trading right at its usual valuation. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
EHC's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $112 | -20% |
| Forward | 21x | $141 | — |
| Fair | 22x | $139 | -1.3% |
| Current | 22x | $141 | — |
| Expensive | 24x | $157 | +11% |
Historical ranges are pointers, not guarantees.
EHC's PE is in its fair range at 22x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EHC Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
EHC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.72 | +4.9% |
| Q3 2026 | $6.40 | +21% |
| Q2 2026 | $6.14 | +20% |
| Q1 2026 | $5.99 | +24% |
| Q4 2025 | $5.54 | +24% |
| Q3 2025 | $5.29 | +28% |
| Q2 2025 | $5.11 | +30% |
| Q1 2025 | $4.84 | +31% |
| Q4 2024 | $4.46 | +29% |
EHC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +8.9% |
| Q2 2026 | $1.6B | +9.6% |
| Q1 2026 | $1.6B | +9% |
| Q4 2025 | $1.5B | +9.9% |
| Q3 2025 | $1.5B | +9.4% |
| Q2 2025 | $1.5B | +12% |
| Q1 2025 | $1.5B | +11% |
| Q4 2024 | $1.4B | +13% |
EHC's revenue has grown year over year for 13 quarters in a row: $1.6B last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +1.4 points |
| Q2 2026 | 18% | +0.3 points |
| Q1 2026 | 19% | +0.7 points |
| Q4 2025 | 18% | +1.8 points |
| Q3 2025 | 16% | +1 points |
| Q2 2025 | 18% | +1.2 points |
| Q1 2025 | 18% | +2.6 points |
| Q4 2024 | 17% | +1.3 points |
EHC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over EHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
EHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.5M | +52% |
| Q2 2026 | $62.3M | -45% |
| Q1 2026 | $150.7M | +20% |
| Q4 2025 | $116.7M | +46% |
| Q3 2025 | $83.7M | -30% |
| Q2 2025 | $113.3M | +87% |
| Q1 2025 | $125.5M | +26% |
| Q4 2024 | $80.1M | +$101.7M |
EHC generated $457M in free cash flow over the past year, up 14% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over EHC on cash flow, with more consistent year-over-year improvement.
EHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -300K shares |
| 1 year | -2.5% | -2.6M shares |
| 3 years | -1.7% | -1.7M shares |
| 5 years | -0.5% | -500K shares |
| Available history | +0.3% | +300K shares |
EHC has 100M diluted shares, down 2.5% from a year ago, with $280M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $57.9M |
| Q2 2026 | $74.2M |
| Q1 2026 | $71.6M |
| Q4 2025 | $76.3M |
| Q3 2025 | $24.9M |
| Q2 2025 | $24.7M |
| Q1 2025 | $32.1M |
| Q4 2024 | $7.5M |
EHC spent $280M buying back its own shares over the past year, about three times what it spent the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 2.1x | Moderate |
EHC's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
EHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.7 | Overbought |
| Stochastic | 88.7 | Overbought |
EHC's weekly RSI is 73 (overbought) and its Stochastic is 89 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EHC PE vs Healthcare Sector
| Metric | EHC | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 15% below |
| PE % | 53 | 29 | 24 pts above |
EHC is trading at 22x earnings, a 15% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.1 | 9.1% above |
| 20 week MA | $122.0 | 15% above |
| 50 week MA | $111.1 | 27% above |
| 100 week MA | $111.2 | 27% above |
| 200 week MA | $93.1 | 51% above |
EHC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.5 | $65.7 | +19% |
| 2021 | $65.7 | $51.0 | -22% |
| 2022 | $51.0 | $59.3 | +16% |
| 2023 | $59.3 | $66.7 | +13% |
| 2024 | $66.7 | $93.6 | +40% |
| 2025 | $93.6 | $107.5 | +15% |
| 2026 YTD | $107.5 | $140.8 | +31% |
EHC has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.